Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Be ≥10 years and ≤17 years of age, when the informed consent is signed

• Has diabetes diagnosed by one of the American Diabetes Association (ADA) criteria.

• Has body mass index (BMI) ≥85th percentile at screening OR participant has a historyof being overweight or obese at time of diagnosis of Type 2 diabetes mellitus (T2DM).

• T2DM for ≥2 years, OR T2DM for <2 years and a fasting C-peptide value >0.6 ng/mL atScreening.

• On stable metformin monotherapy (≥1500 mg/day, for ≥8 weeks prior to Screening, ORon a stable metformin dose (≥1500 mg/day, for ≥8 weeks prior to Screening and astable dose of insulin for ≥8 weeks prior to Screening.

• Contraceptive use by male participants should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies.

• Is a non-sterilized female who is currently not sexually active OR who agrees toabstain from heterosexual activity OR who agrees to start contraception prior toinitiating sexual activity and who agrees to use an adequate method ofcontraception. Contraceptive use by females should be consistent with localregulations regarding the methods of contraception for those participating inclinical studies.

• Have a family member or adult who, along with the participant, will be closelyinvolved in the participant's daily activities (in the opinion of the investigator)and in the participant's treatment and study procedures.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has known type 1 diabetes mellitus or documented evidence of positive diabetesautoantibodies performed when participant was diagnosed with diabetes.

• Has known monogenic diabetes, or secondary diabetes.

• Has symptomatic hyperglycemia and/or moderate to large ketonuria requiring immediateinitiation of another antihyperglycemic agent, including insulin.

• Has a known hypersensitivity or intolerance to any sodium glucose co-transporter 2 (SGLT2) inhibitor.

• Is pregnant, or breast feeding or is expecting to conceive or donate eggs during thestudy, including 14 days following the last dose of study medication.

• Has previously taken an SGLT2 inhibitor (such as canagliflozin, dapagliflozin,empagliflozin, or ertugliflozin) or was enrolled in a study for these agents.

• Has a history of idiopathic acute pancreatitis or chronic pancreatitis.

• Has a history of severe hypoglycemia while on insulin.